Winston Kung Biography and Net Worth

Director of Corbus Pharmaceuticals

Winston Kung currently serves as Chief Financial Officer of Arrivent BioPharma, a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics. Prior to Arrivent, Mr. Kung was Chief Financial Officer and Chief Operating Officer at PMV Pharmaceuticals. Prior to joining PMV Pharma, Mr. Kung was Vice President of Business Development and Global Alliances at Celgene, and previously held the position of Chief Business Officer at Celgene Cellular Therapeutics. Before his role at Celgene, Mr. Kung held senior positions at Citigroup’s Global Healthcare Investment Banking group and at Lehman Brothers’ Global Mergers and Acquisition group. Mr. Kung also led multiple transactions as part of Genentech’s and Amgen’s Business and Corporate Development groups. Mr. Kung earned his M.B.A from Harvard Business School and a B.A. in Biology and International Relations from Brown University.

What is Winston Kung's net worth?: The estimated net worth of Winston Kung is at least $112.34 thousand as of June 10th, 2026. Mr. Kung owns 12,140 shares of Corbus Pharmaceuticals stock worth more than $112,344 as of July 24th. This net worth evaluation does not reflect any other investments that Mr. Kung may own. Learn More about Winston Kung's net worth.
How do I contact Winston Kung?: The corporate mailing address for Mr. Kung and other Corbus Pharmaceuticals executives is 500 River Ridge Drive, Norwood MA, 02062. Corbus Pharmaceuticals can also be reached via phone at (617) 963-0100 and via email at [email protected]. Learn More on Winston Kung's contact information.
Has Winston Kung been buying or selling shares of Corbus Pharmaceuticals?: Winston Kung has not been actively trading shares of Corbus Pharmaceuticals within the last three months. Most recently, Winston Kung sold 2,026 shares of the business's stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $7.91, for a transaction totalling $16,025.66. Following the completion of the sale, the director now directly owns 12,140 shares of the company's stock, valued at $96,027.40. Learn More on Winston Kung's trading history.
Who are Corbus Pharmaceuticals' active insiders?: Corbus Pharmaceuticals' insider roster includes Anne Altmeyer (Director), Yuval Cohen (CEO), John Jenkins (Director), and Winston Kung (Director). Learn More on Corbus Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Corbus Pharmaceuticals?: During the last twelve months, Corbus Pharmaceuticals insiders bought shares 2 times. They purchased a total of 13,500 shares worth more than $101,205.00. During the last twelve months, insiders at the biopharmaceutical company sold shares 10 times. They sold a total of 86,641 shares worth more than $1,177,188.36. The most recent insider tranaction occured on June, 10th when Director Winston Kung sold 2,026 shares worth more than $16,025.66. Insiders at Corbus Pharmaceuticals own 3.5% of the company. Learn More about insider trades at Corbus Pharmaceuticals.
Information on this page was last updated on 6/10/2026.

Winston Kung Insider Trading History at Corbus Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/10/2026	Sell	2,026	$7.91	$16,025.66	12,140

Winston Kung Buying and Selling Activity at Corbus Pharmaceuticals

Corbus Pharmaceuticals Company Overview

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Today's Range

Now: $9.22

$8.93

$9.36

50 Day Range

MA: $8.79

$7.38

$11.51

2 Week Range

Now: $9.22

$7.12

$20.56

Volume

115,366 shs

Average Volume

332,724 shs

Market Capitalization

$170.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.55